Ximelagatran
Ximelagatran
Ximelagatran (/ziːmɛləˈɡætræn/) is an anticoagulant that has been investigated for its potential use in the prevention of thrombosis and thromboembolism in various clinical scenarios. However, its development was discontinued due to concerns about its safety profile, particularly hepatotoxicity.
Etymology
The name "Ximelagatran" is derived from the chemical structure of the drug. The prefix "Ximel-" is an arbitrary designation, while "-agatran" is a common suffix for direct thrombin inhibitors.
Pharmacology
Ximelagatran is a prodrug that is converted to the active agent, melagatran, in the body. It works by directly inhibiting thrombin, an enzyme that plays a central role in the clotting cascade. This prevents the conversion of fibrinogen to fibrin, thereby inhibiting clot formation.
Clinical Use
Ximelagatran was studied for use in the prevention of stroke and systemic embolic events in patients with atrial fibrillation, and for the prevention and treatment of venous thromboembolism. However, its development was discontinued after phase III trials due to concerns about hepatotoxicity.
Related Terms
- Anticoagulant
- Thrombosis
- Thromboembolism
- Prodrug
- Thrombin
- Fibrinogen
- Fibrin
- Stroke
- Atrial fibrillation
- Venous thromboembolism
- Hepatotoxicity
External links
- Medical encyclopedia article on Ximelagatran
- Wikipedia's article - Ximelagatran
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski